SELLAS receives orphan drug designation for PTCL therapy
Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95
Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.